(Q43125789)

14 November 2017

Drug discovery: inhibitors that activate (English)

1 reference

14 November 2017

1 reference

2

Pasi A Jänne

1 reference

14 November 2017

Karen Cichowski

1

1 reference

PubMed ID

20237552

14 November 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

14 November 2017

1 reference

14 November 2017

464

1 reference

14 November 2017

358-359

1 reference

14 November 2017

7287

1 reference

https://scigraph.springernature.com/pub.10.1038/464358a

14 November 2017

0 references

cites work

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

12 December 2020

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

1 reference

12 December 2020

Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas

1 reference

12 December 2020

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

12 December 2020

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

12 December 2020

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

1 reference

12 December 2020

Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors

1 reference

12 December 2020

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

1 reference

12 December 2020

Identifiers

DOI

10.1038/464358A

1 reference

PubMed ID

20237552

Dimensions Publication ID

14 November 2017

0 references

1 reference

PubMed ID

20237552